DuPont today submitted documentation related to DuPont Light Stabilizer 210, a new titanium dioxide product with a sizeable percentage of particles in the nanoscale, as a demonstration of its support for the new U.S. Environmental Protection Agency Nanoscale Materials Stewardship Program. This submission is the first received by the EPA under the new program, which was launched Monday.
dermaCM, announces successful findings of a double blind human taste test using proprietary nanolipidic particles to mask the taste of sodium chloride in distilled water preparations. Taste-masking nanotechnology can be used to mask unpleasant tastes in beverage, pharmaceuticals and nutricuetical preparations, vastly improving consumer acceptance, patient compliance and user satisfaction.
pSivida Limited today announced the results of the Phase IIa clinical trial of BrachySil for the treatment of advanced, inoperable pancreatic cancer presented at American Society of Clinical Oncolgy-GI. The trial, designed as a safety study, successfully showed that BrachySil, in combination with standard chemotherapy (gemcitabine), was well tolerated with no clinically significant adverse events related to BrachySil.
Thermo Fisher Scientific Inc. announces that it has been awarded a US Patent on Spectrometric Data Cleansing. This patent describes a method for filtering artifacts from Raman spectra and is of particular use in removing the distorted data points generated by cosmic ray interference.
Cummins Filtration, a leader in filtration, exhaust, coolant and chemical technology for all engine-powered systems, announced that it has entered into a cooperation agreement with Elmarco s.r.o, a Czech nanotechnology designer. The strategic objective of the agreement is to develop innovative solutions in nanofiber media technologies to allow Cummins Filtration to better serve global application needs in motor vehicle and related filtration systems.
Nanotech Briefs has announced a Call for Nominations for its fourth annual Nano 50 awards competition, which launched on January 7. The Nano 50 recognizes the top 50 technologies, innovators, and products with the greatest potential to advance the commercialization of nanotechnology.
T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced significant research findings that support the advancement and development of nanoparticle-based, magnetic resonance technology that offer rapid, portable diagnostic testing.
Arrowhead Research Corporation announced today the appointment of Dr. Mauro Ferrari to its newly established Board of Scientific Strategy. He is one of the most well-known experts in leveraging nanotechnology to treat and diagnose cancer. Dr. Ferrari will serve as a Director of Scientific Strategy and will be integral in building out the new advisory board and guiding Arrowhead's operations and strategic plan.
AMI Semiconductor (NASDAQ: AMIS), a leading designer and manufacturer of state-of-the-art mixed-signal and digital products for the automotive, medical, industrial, aerospace, and high-voltage communication markets, has entered into a new two-year collaboration program with IMEC - Europe's leading independent research center in the field of nanoelectronics - to develop AMI Semiconductor‚??s future Smart Power Technologies.
Nanotechnology-enabled energy technologies, printable electronics and nanobiotechnology are just three of the many panel topics to be presented at the IBF's 2008 Nano Applications and Advanced Materials Forum that will take place February 5-6 in Indian Wells, California.
Keller and Heckman LLP and NanoReg are hosting a nanoregulation workshop on March 20, 2008 in Baltimore, Maryland. This conference is immediately following the Global Chemical Regulations Conference at the Marriott Baltimore Waterfront Hotel.
Arrowhead's new President and Chief Executive Officer. On December 3, 2007, Dr. Anzalone was granted an option to purchase 2,000,000 shares of the common stock of Arrowhead at an exercise price of $3.92, the closing price of Arrowhead's shares on that date.